KEY TAKEAWAYS
- The PROMETCO observational study aimed to track and evaluate the needs and outcomes of pts with mCRC.
- The result revealed that patient characteristics, survival rates, and treatment practices align with the global cohort.
PROMETCO was the 1 international, prospective, real-world (RW) study (NCT03935763) to investigate the continuum of care in patients (pts) with metastatic colorectal cancer (mCRC) and to provide RW survival evidence.
Francisca E. Marti Marti and the team aimed to assess the treatment patterns, outcomes, and overall survival (OS) of pts with mCRC.
Researchers analyzed 76 adult pts with mCRC, who had 2 progressions since diagnosis and were open to further treatment. The median age of the pts was 65 (39-86) with men in majority (60.5%).
During the observation, baseline demographics, treatment patterns, and molecular data for the entire pts cohort were studied. They also examined endpoint data, including OS and progression-free survival (PFS), defined from the start of treatment until disease progression, death, or new treatment. This analysis focused on pts who completed the study by July 2023.
The results showed that among 76 pts enrolled from 10 sites, 39.5% were RAS mutants, 34.2% were RAS/BRAF wild types, and 6.6% were BRAF mutants. The microsatellite instability (MSI) status was unknown for 59.2% pts, while 1.3% were MSI high, 9.2% were MSI low, and 30.3% were microsatellite stable.
The median time from mCRC diagnosis to enrolment was 21.6 months. Patients received various treatments, including fluoropyrimidine (98.7%), oxaliplatin (81.6%), irinotecan (98.7%), anti-VEGF (2.6%), an anti-EGFR antibody (44.7%), FTD/TPI (85.5%), or regorafenib (1.3%).
By July 2023, 68 pts (89%) were included in the interim survival analysis. The median (m)OS from mCRC diagnosis was 36.5 [95% CI: 26.94-42.15] months, from PROMETCO inclusion was 5.5 months, and from the start of 3rd-line treatment was 5.3 months. Median (m)PFS was 6.6 months in 1st-line, 4.6 months in 2nd-line, 2.4 months in 3rd-line, and 2.2 months in 4th-line.
The study concluded that patient characteristics, survival rates, and treatment practices are comparable to the global cohort, reflecting current drug access and prescribing patterns.
The trial was sponsored by Servier Affaires Médicales
Source: https://cslide.ctimeetingtech.com/esmogi24hybrid/attendee/confcal/show/session/3
Clinical Trial: https://www.clinicaltrials.gov/study/NCT03935763
Marti FEM, Raman E, Brady D, et al. (2024). “Real-world data on overall and progression-free survival for patients (pts) with metastatic colorectal cancer (mCRC) for the United Kingdom (UK) cohort of the PROMETCO study (PROMETCO-UK).” Presented at ESMO GI 2024 (Abstract 102P).
